Goldman Sachs Group »

Protalix Biotherapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Protalix Biotherapeutics (PLX) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Protalix Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protalix Biotherapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protalix Biotherapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $186k 105k 1.78
2023-09-30 $179k 108k 1.66
2023-06-30 $100k 50k 2.00

More positions owned by Goldman Sachs Group

Spdr S&p 500 Etf Tr CMN (SPY)
Apple CMN (AAPL)
Microsoft Corp CMN (MSFT)
Ishares Tr CMN (IWM)
Amazon CMN (AMZN)
Nvidia Corporation CMN (NVDA)
Invesco Qqq Tr CMN (QQQ)
Ishares Tr CMN (IVV)
Tesla CMN (TSLA)
Alphabet CMN (GOOGL)
Meta Platforms CMN (META)
Vanguard Index Fds CMN (VOO)
Visa CMN (V)
Ishares Tr CMN (HYG)
Ishares Tr CMN (EFA)

View all positions for Goldman Sachs Group

Top funds holding Protalix Biotherapeutics

GSA Capital Partners
Vanguard Group
Bank of America Corporation
Bank of New York Mellon
Charles Schwab Investment Management
Barclays
Goldman Sachs Group
Citadel Advisors
Orin Green Financial
UBS Group
OZ Management
Rhumbline Advisers
Connor, Clark & Lunn Investment Management
Bailard
Commonwealth Equity Services

View all funds holding Protalix Biotherapeutics